drugset
drugset / Trial / NCT07522073

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073 ↗

Phase 3 Recruiting 588 enrolled Incyte Corporation Qiagen Manchester Limited · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).

Timeline

Start
2026-04-09
Primary completion
2028-09-15
Completion
2029-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject INCB161734 Unknown — Oral
Background GEMNabP Unknown — —
Background mFOLFIRINOX Unknown — —

Indications

cancer